Ernexa Therapeutics Inc.

For the period ended Jun 30, 2026. Filed Aug 6, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 6, 2026

ERNA$2.01-2.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity (Deficit)

For the three and six months ended June 30, 2026 and 2025 (unaudited)

(In thousands)

Series A Preferred Stock · Common Stock · Additional Paid-in · Accumulated
	Shares	Amount	Shares	Amount	Capital	Deficit	Total
Balances at April 1, 2026	156	$1	1,166	$6	$257,994	$(251,142)	$6,859
Issuance of common stock to consultant for services	-	-	2	-	24	-	24
Issuance of common stock to Series A preferred stockholders in lieu of cash dividends	-	-	1	-	8	(8)	-
Issuance of common stock under ATM, net	-	-	1	-	6	-	6
Stock-based compensation	-	-	-	-	320	-	320
Net loss	-	-	-	-	-	(4,009)	(4,009)
Balances at June 30, 2026	156	$1	1,170	$6	$258,352	$(255,159)	$3,200

Series A Preferred Stock · Common Stock · Additional Paid-in · Accumulated
	Shares	Amount	Shares	Amount	Capital	Deficit	Total
Balances at January 1, 2026	156	$1	314	$2	$248,034	$(245,636)	$2,401
Issuance of common stock, prefunded warrants and warrants in connection with public offering, net	-	-	769	4	9,537	-	9,541
Issuance of common stock from the exercise of prefunded warrants, net	-	-	80	-	18	-	18
Issuance of common stock to consultant for services	-	-	5	-	120	-	120
Issuance of common stock to Series A preferred stockholders in lieu of cash dividends	-	-	1	-	8	(8)	-
Issuance of common stock under ATM, net	-	-	1	-	6	-	6
Stock-based compensation	-	-	-	-	629	-	629
Net loss	-	-	-	-	-	(9,515)	(9,515)
Balances at June 30, 2026	156	$1	1,170	$6	$258,352	$(255,159)	$3,200

Series A Preferred Stock · Common Stock · Additional Paid-in · Accumulated
	Shares	Amount	Shares	Amount	Capital	Deficit	Total
Balances at April 1, 2025	156	$1	139	$1	$233,786	$(239,738)	$(5,950)
Issuance of common stock to Series A preferred stockholders in lieu of cash dividends	-	-	-	-	8	(8)	-
Issuance of common stock to consultant for services	-	-	1	-	47	-	47
Issuance of common stock in connection with settlement	-	-	1	-	69	-	69
Issuance of common stock and prefunded warrants in connection with private placement	-	-	159	1	13,047	-	13,048
Stock-based compensation	-	-	-	-	369	-	369
Net loss	-	-	-	-	-	(3,139)	(3,139)
Balances at June 30, 2025	156	$1	300	$2	$247,326	$(242,885)	$4,444

Series A Preferred Stock · Common Stock · Additional Paid-in · Accumulated
	Shares	Amount	Shares	Amount	Capital	Deficit	Total
Balances at January 1, 2025	156	$1	137	$1	$233,235	$(231,536)	$1,701
Issuance of common stock to Series A preferred stockholders in lieu of cash dividends	-	-	-	-	8	(8)	-
Issuance of common stock in connection with exercise of prefunded warrants	-	-	2	-	4	-	4
Issuance of common stock to consultant for services	-	-	1	-	93	-	93
Issuance of common stock in connection with settlement	-	-	1	-	69	-	69
Issuance of common stock and prefunded warrants in connection with private placement	-	-	159	1	13,047	-	13,048
Stock-based compensation	-	-	-	-	870	-	870
Net loss	-	-	-	-	-	(11,341)	(11,341)
Balances at June 30, 2025	156	$1	300	$2	$247,326	$(242,885)	$4,444

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.